Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming registration-directed trial of tipifarnib in HRAS mutant HNSCC – – …